Singapore’s nascent biomedical industry is fairly young by global standards, just a few decades old compared to the far longer history of other biomedical hubs like London and Boston. However, despite the Singaporean biomedical sector’s relative newness, the city-state is now Asia’s preferred location for such procedures as skin cancer removal, chemotherapy, and other oncological treatments.

Here are the top 5 research-focused healthtech startups in Singapore

As with many things about Singapore, this regional dominance comes as no accident. A series of calculated policy decisions set in motion decades ago are now bearing fruit for the country, consequently fuelling even more growth in its life sciences ecosystem. The country continues to strengthen its position as a cancer care hub with an evolving multipronged approach. Singapore’s current status as a leading destination for oncological treatments can be attributed to several key factors:

1. Government investment and support

For decades, the Singaporean government has viewed its biomedical sector as a key strategic growth area. Unlike many other countries, however, Singapore has shown consistency in meeting its long-term objectives.

Notably, the Biomedical Sciences (BMS) initiative was launched in 2000 to boost industries such as pharmaceuticals, biotechnology, medical technology, and healthcare. Despite the high initial cost and poor prospects of immediate returns, the BMS initiative was consistently supported for several years. Today, cancer research and other life sciences areas are producing net positives for the country, with pharmaceuticals, medical tourism, and biotechnology accounting for a serious proportion of the economy.

2. State-of-the-art facilities

In the 2000s, Singapore’s government made a deliberate decision to invest in expensive research infrastructure to support cutting-edge research. While it did take some time for these investments to bear fruit, these facilities now serve as a vital nexus between cancer researchers in academia and industry. Public investment in these facilities has made it possible to pursue lines of research that were not previously viable in the short term, laying the foundation for practical applications in cancer treatments years down the line.

3. Skilled medical practitioners

Thanks to decades of investment, Singapore is now home to an international pool of highly skilled medical practitioners and researchers who specialise in cancer treatments. Domestic institutions like the National University Cancer Institute, Singapore and the Cancer Science Institute of Singapore (CSI Singapore) are just two of the more prominent names at the forefront of cancer research and treatment, producing local talents and attracting promising medical professionals from overseas.

4. A highly productive academic sector

Singapore’s academic institutions play a pivotal role in driving cancer research and treatment within the city-state. The country’s institutions train some of the world’s top oncologists and cancer researchers, providing the local biomedical sector with a steady supply of extremely specialised talent. Notably, the National University of Singapore (NUS) houses the aforementioned CSI Singapore, which was awarded a Research Centre of Excellence grant for its contributions to cancer research.

5. Close ties between industry and academia

Despite its academic strengths and steady public investments, the Singaporean biomedical industry has faced challenges in translating scientific discoveries into viable business ventures. Recent initiatives like 65LAB aim to bridge this gap by providing funding and support to academic entrepreneurs and fostering collaboration between research institutions and industry partners. Additionally, multiple government bodies now exist to provide platforms for collaboration between public sector research institutions and industry partners.

6. Geographic location

Singapore’s strategic geographic advantage offers it an enviable reach when accessing international investors and talent pools. The country’s status as the “Gateway to Asia” facilitates simpler collaboration and partnerships with global pharmaceutical and biotechnology companies while also encouraging the inflow of international talent. 

7. Consistent international collaboration

The city-state’s public and private sectors have a history of actively collaborating with international partners to accelerate cancer drug development. Strategic partnerships with major cancer research organisations like Cancer Research Horizons and UK-based companies like Plasticell show its willingness to pursue oncology research at a wider scale.

8. Innovative domestically developed cancer therapies

Singapore-based researchers have consistently developed new therapeutic approaches for cancer treatment. Domestic research breakthroughs such as the discovery of humanised antibodies and advancements in genomics, continue to offer new avenues for targeted therapies and personalised medicine, revolutionising cancer treatment paradigms and improving patient outcomes globally.

9. A credible regulatory environment

Though it is characterised by a willingness to pursue otherwise ignored areas of research, Singapore’s biomedical sector is still framed by a robust regulatory environment, with the Health Sciences Authority (HSA) playing a central role. This well-implemented and nuanced regulation has helped Singapore’s domestic cancer treatment and research gain an overall positive reputation throughout the world. 

Singapore’s growing impact on global cancer care

As Singapore continues to strengthen its life sciences ecosystem, it is poised to become a global centre for cancer treatment and care at the level of its much more established counterparts in Europe and North America. With the convergence of government support, academic excellence, and industry collaboration, Singapore is already addressing the challenges of cancer, not only in Asia but worldwide.